**Correction to: J Headache Pain**

**https://doi.org/10.1186/s10194-019-1024-x**

After publication of our article \[[@CR1]\] we were notified that the data presented in the upper row of Fig. [7](#Fig1){ref-type="fig"} was inadvertently the least square mean change from baseline (standard error) at Month 6 rather than the overall average of Month 3 and Month 6. The figure legend and discussion of the data in the text were and are correct. The error was only in the upper row of Fig. [7](#Fig1){ref-type="fig"}. The legend for Fig. [7](#Fig1){ref-type="fig"} did not require revision. Fig. 7The overall least-squares (LS) mean change in Migraine Disability Assessment (MIDAS) total Score for the average of Months 3 and 6 is shown for patients with LFEM and HFEM receiving placebo, 120-mg, or 240-mg of galcanezumab in the upper row. The LS mean changes in MIDAS total score at Months 3 and 6 for patients receiving these treatments is shown in the bottom row for patients with LFEM and with HFEM. \*\*\**p* ≤ .001, \*\**p* ≤ .01, \**p* ≤ .05 vs placebo

The original article can be found online at 10.1186/s10194-019-1024-x
